Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

High total metabolic tumor volume at baseline allows discrimination of survival even in patients aged 60 to 80 years responding to R-CHOP.

Vercellino L, Cottereau AS, Casasnovas RO, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Obéric L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban CJ, López-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, Salles GA, Gaulard P, Meignan M, Thieblemont C.

Blood. 2020 Jan 24. pii: blood.2019003526. doi: 10.1182/blood.2019003526. [Epub ahead of print]

PMID:
31978225
2.

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma.

Reger de Moura C, Vercellino L, Jouenne F, Baroudjian B, Sadoux A, Louveau B, Delyon J, Serror K, Goldwirt L, Merlet P, Bouquet F, Battistella M, Lebbé C, Mourah S.

Transl Oncol. 2020 Feb;13(2):275-286. doi: 10.1016/j.tranon.2019.10.003. Epub 2019 Dec 23.

3.

Early 18F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab.

Chen A, Mokrane FZ, Schwartz L, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Dulery R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Armand P, Houot R, Dercle L.

J Nucl Med. 2019 Oct 18. pii: jnumed.119.232827. doi: 10.2967/jnumed.119.232827. [Epub ahead of print]

PMID:
31628220
4.

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S.

Haematologica. 2020 Mar;105(3):e95-e97. doi: 10.3324/haematol.2018.215582. Epub 2019 Aug 14. No abstract available.

5.

Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists.

Mahevas M, Van Eeckhoudt S, Moulis G, Limal N, Languille L, Bierling P, Dossier A, Duriez F, Galicier L, Morin AS, Tamburini J, Chaoui D, Bouscary D, Jijakli AAL, Khellaf M, Vaida I, Michel M, Vercellino L, Jaddi H, Yollant A, Dosquet C, Godeau B, Chomienne C.

Br J Haematol. 2019 Aug;186(3):e44-e47. doi: 10.1111/bjh.15890. Epub 2019 Apr 4. No abstract available.

PMID:
30950041
6.

CRTC1-TRIM11 Fusion in a Case of Metastatic Clear Cell Sarcoma: Are CRTC1-TRIM11 Fusion-bearing Tumors Melanocytomas or Clear Cell Sarcomas?

Bontoux C, Baroudjian B, Le Maignan C, Vercellino L, Farges C, Guillemot D, Pierron G, Lebbé C, Battistella M.

Am J Surg Pathol. 2019 Jun;43(6):861-863. doi: 10.1097/PAS.0000000000001217. No abstract available.

PMID:
30676334
7.

Early metabolic response to chemoradiotherapy by interim FDG PET/CT is associated with better overall survival and histological response in esophageal cancers.

Hammoudi N, Hennequin C, Vercellino L, Costantini A, Valverde A, Cattan P, Quéro L.

Dig Liver Dis. 2019 Jun;51(6):887-893. doi: 10.1016/j.dld.2018.12.006. Epub 2018 Dec 23.

PMID:
30630738
8.

Osteopenia and fractures associated with long-term therapy with MEK inhibitors.

Dumas M, Laly P, Gottlieb J, Vercellino L, Paycha F, Bagot M, Baroudjian B, Madelaine I, Basset-Seguin N, Eftekhari P, Pagès C, Lebbé C, Lioté F.

Melanoma Res. 2018 Dec;28(6):641-644. doi: 10.1097/CMR.0000000000000490.

PMID:
30124538
9.

Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion.

Lorillon G, Jouenne F, Baroudjian B, de Margerie-Mellon C, Vercellino L, Meignin V, Lebbe C, Vassallo R, Mourah S, Tazi A.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):675-678. doi: 10.1164/rccm.201802-0275LE. No abstract available.

PMID:
29694792
10.

Sentinel Lymph Node Biopsy in Cutaneous Squamous Cell Carcinoma Series of 37 Cases and Systematic Review of the Literature.

Lhote R, Lambert J, Lejeune J, Gottlieb J, Badaoui A, Battistella M, Roux J, Pages C, Vercellino L, Vilmer C, Le Maignan C, Escande C, MBarek B, Bagot M, Lebbé C, Basset-Seguin N.

Acta Derm Venereol. 2018 Jul 11;98(7):671-676. doi: 10.2340/00015555-2942. Review.

11.

PD-1 blockade with nivolumab in endemic Kaposi sarcoma.

Delyon J, Bizot A, Battistella M, Madelaine I, Vercellino L, Lebbé C.

Ann Oncol. 2018 Apr 1;29(4):1067-1069. doi: 10.1093/annonc/mdy006. No abstract available.

12.

The full spectrum of Castleman disease: 273 patients studied over 20 years.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gérard L, Galicier L.

Br J Haematol. 2018 Jan;180(2):206-216. doi: 10.1111/bjh.15019. Epub 2017 Nov 16.

PMID:
29143319
13.

18F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin.

Ram-Wolff C, Vercellino L, Brice P, La Selva R, Bagot M.

Eur J Dermatol. 2017 Oct 1;27(5):496-504. doi: 10.1684/ejd.2017.3083.

PMID:
28721937
14.

Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.

Gauci ML, Laly P, Leonard-Louis S, Behin A, Gottlieb J, Madelaine-Chambrin I, Baroudjian B, Da-Meda L, Mourah S, Battistella M, Basset-Seguin N, Bagot M, Pages C, Vercellino L, Maisonobe T, Lebbé C.

Melanoma Res. 2017 Oct;27(5):511-515. doi: 10.1097/CMR.0000000000000377.

PMID:
28692456
15.

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab.

Gauci ML, Baroudjian B, Laly P, Madelaine I, Da Meda L, Vercellino L, Bagot M, Lioté F, Pages C, Lebbé C.

Semin Arthritis Rheum. 2017 Oct;47(2):281-287. doi: 10.1016/j.semarthrit.2017.03.003. Epub 2017 Mar 8.

PMID:
28438383
16.

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, Kiladjian JJ.

J Nucl Med. 2017 Oct;58(10):1603-1608. doi: 10.2967/jnumed.116.188508. Epub 2017 Mar 30.

17.

Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.

Lemarignier C, Martineau A, Teixeira L, Vercellino L, Espié M, Merlet P, Groheux D.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1145-1154. doi: 10.1007/s00259-017-3641-4. Epub 2017 Feb 10.

PMID:
28188325
18.

18F-FDG labelling of hematopoietic stem cells: Dynamic study of bone marrow homing by PET-CT imaging and impact on cell functionality.

Faivre L, Chaussard M, Vercellino L, Vanneaux V, Hosten B, Teixera K, Parietti V, Merlet P, Sarda-Mantel L, Rizzo-Padoin N, Larghero J.

Curr Res Transl Med. 2016 Jul - Sep;64(3):141-148. doi: 10.1016/j.retram.2016.06.002. Epub 2016 Sep 28.

PMID:
27765274
19.

18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis.

Obert J, Vercellino L, Van Der Gucht A, de Margerie-Mellon C, Bugnet E, Chevret S, Lorillon G, Tazi A.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):598-610. doi: 10.1007/s00259-016-3521-3. Epub 2016 Sep 20.

PMID:
27645693
20.

FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review.

Groheux D, Quere G, Blanc E, Lemarignier C, Vercellino L, de Margerie-Mellon C, Merlet P, Querellou S.

Diagn Interv Imaging. 2016 Oct;97(10):1003-1017. doi: 10.1016/j.diii.2016.06.020. Epub 2016 Aug 24. Review.

21.

Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma.

Lorillon G, Mourah S, Vercellino L, de Margerie-Mellon C, Pagès C, Goldwirt L, Lebbe C, Tost J, Tazi A.

Ann Oncol. 2016 Dec;27(12):2305-2307. doi: 10.1093/annonc/mdw299. Epub 2016 Aug 8. No abstract available.

22.

Nivolumab-Induced Sarcoid-Like Granulomatous Reaction in a Patient With Advanced Melanoma.

Danlos FX, Pagès C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, Jebali M, Bagot M, Tazi A, Lebbé C.

Chest. 2016 May;149(5):e133-6. doi: 10.1016/j.chest.2015.10.082.

PMID:
27157227
23.

Extrathoracic investigation in adult patients with isolated pulmonary langerhans cell histiocytosis.

Tazi A, de Margerie-Mellon C, Vercellino L, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S.

Orphanet J Rare Dis. 2016 Feb 2;11:11. doi: 10.1186/s13023-016-0387-1.

24.

Priming Dental Pulp Stem Cells With Fibroblast Growth Factor-2 Increases Angiogenesis of Implanted Tissue-Engineered Constructs Through Hepatocyte Growth Factor and Vascular Endothelial Growth Factor Secretion.

Gorin C, Rochefort GY, Bascetin R, Ying H, Lesieur J, Sadoine J, Beckouche N, Berndt S, Novais A, Lesage M, Hosten B, Vercellino L, Merlet P, Le-Denmat D, Marchiol C, Letourneur D, Nicoletti A, Vital SO, Poliard A, Salmon B, Muller L, Chaussain C, Germain S.

Stem Cells Transl Med. 2016 Mar;5(3):392-404. doi: 10.5966/sctm.2015-0166. Epub 2016 Jan 21.

25.

¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.

Groheux D, Biard L, Giacchetti S, Teixeira L, Hindié E, Cuvier C, Vercellino L, Merlet P, de Roquancourt A, de Cremoux P, Resche-Rigon M, Espié M.

J Nucl Med. 2016 Apr;57(4):536-43. doi: 10.2967/jnumed.115.163907. Epub 2015 Dec 23.

26.

Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib.

Mourah S, Lorillon G, Meignin V, Vercellino L, de Margerie-Mellon C, Pages C, Goldwirt L, How-Kit A, Tost J, Lebbe C, Tazi A.

Blood. 2015 Dec 10;126(24):2649-52. doi: 10.1182/blood-2015-06-650036. Epub 2015 Oct 14. No abstract available.

PMID:
26468227
27.

18F-Choline PET/CT and Prostate MRI for Staging Patients With Biochemical Relapse After Irradiation for Prostate Cancer.

Quero L, Vercellino L, de Kerviler E, Mongiat-Artus P, Culine S, Merlet P, Ravery V, Meria P, Desgrandchamps F, Hennequin C.

Clin Nucl Med. 2015 Nov;40(11):e492-5. doi: 10.1097/RLU.0000000000000932.

PMID:
26252326
28.

Breast infiltration by relapsed acute lymphoblastic leukaemia on FDG PET/CT.

Luzurier A, Van Der Gucht A, Blanc E, Lengline E, Groheux D, Vercellino L, Merlet P.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):811-2. doi: 10.1007/s00259-014-2977-2. Epub 2015 Jan 9. No abstract available.

PMID:
25573633
29.

[Acid sphingomyelinase deficiency and spleen trauma: splenectomy or not splenectomy?].

Lidove O, Le Fèvre L, Goasguen N, Jamali M, Vercellino L, Garnier M, Khellaf M, Belmatoug N, Ziza JM.

Rev Med Interne. 2015 Sep;36(9):619-22. doi: 10.1016/j.revmed.2014.10.367. Epub 2014 Nov 5. French.

PMID:
25479761
30.

¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.

Groheux D, Hindié E, Marty M, Espié M, Rubello D, Vercellino L, Bousquet G, Ohnona J, Toubert ME, Merlet P, Misset JL.

Eur J Radiol. 2014 Oct;83(10):1925-33. doi: 10.1016/j.ejrad.2014.05.037. Epub 2014 Jun 17.

PMID:
24985086
31.

Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.

Grellier JF, Vercellino L, Leblanc T, Merlet P, Thieblemont C, Weinmann P, Toubert ME, Berenger N, Brière J, Brice P.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2023-30. doi: 10.1007/s00259-014-2825-4. Epub 2014 Jun 26.

PMID:
24965842
32.

Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.

Bousquet G, Feugeas JP, Ferreira I, Vercellino L, Jourdan N, Bertheau P, de Bazelaire C, Barranger E, Janin A.

Breast Cancer Res. 2014 Feb 11;16(1):401. doi: 10.1186/bcr3615.

33.

Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse.

Tauber M, Pages C, La Selva R, Schneider P, Chardin J, Osio A, Mourah S, Culine S, Vercellino L, Bagot M, Lebbé C.

Eur J Dermatol. 2013 Sep-Oct;23(5):702-3. doi: 10.1684/ejd.2013.2143. No abstract available.

PMID:
24135270
34.

HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.

Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, Cuvier C, Coussy F, Espié M, Hindié E.

Br J Cancer. 2013 Sep 3;109(5):1157-64. doi: 10.1038/bjc.2013.469. Epub 2013 Aug 13.

35.

Role of SPECT/CT in sentinel lymph node detection in patients with breast cancer.

Vercellino L, Ohnona J, Groheux D, Slama A, Colletti PM, Chondrogiannis S, Merlet P, Toubert ME, Rubello D.

Clin Nucl Med. 2014 May;39(5):431-6. doi: 10.1097/RLU.0b013e31829af8c0.

PMID:
23877520
36.

[Extravasation of radiopharmaceuticals: preventive measures and management recommended by SoFRa (Société Française de Radiopharmacie)].

Barré E, Nguyen ML, Bruel D, Fournel C, Hosten B, Lao S, Vercellino L, Rizzo-Padoin N.

Ann Pharm Fr. 2013 Jul;71(4):216-24. doi: 10.1016/j.pharma.2013.05.001. Epub 2013 Jun 14. Review. French.

PMID:
23835019
37.

Breast cancer patient with an uncommon lymphatic drainage evidenced by SPECT/CT.

Groheux D, Ferré R, Rubello D, Vercellino L, Hindié E.

Clin Nucl Med. 2014 Feb;39(2):e176-9. doi: 10.1097/RLU.0b013e3182995991.

PMID:
23797233
38.

Cryptorchidism as a potential source of misinterpretation in ¹⁸FDG-PET imaging in restaging lymphoma patients.

Groheux D, Teyton P, Vercellino L, Ferretti A, Rubello D, Hindié E.

Biomed Pharmacother. 2013 Jul;67(6):533-8. doi: 10.1016/j.biopha.2013.04.011. Epub 2013 May 7.

PMID:
23721825
39.

The 2009 revised American Thyroid Association guidelines for thyroid cancer: multifocality in T1 tumors in question, for or against a more minimalist approach?

Meas T, Vercellino L, Faugeron I, Toubert ME.

Thyroid. 2013 Aug;23(8):1042-3. doi: 10.1089/thy.2012.0222. Epub 2013 Jul 20. No abstract available.

PMID:
23441600
40.

Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas.

Cuenca X, Hennequin C, Hindié E, Rivera S, Vercellino L, Baruch-Hennequin V, Gornet JM, Cattan P, Chirica M, Quéro L.

Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):477-85. doi: 10.1007/s00259-012-2325-3. Epub 2013 Feb 1.

PMID:
23371374
41.

Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C, de Roquancourt A, Vercellino L, Toubert ME, Merlet P, Espié M.

J Natl Cancer Inst. 2012 Dec 19;104(24):1879-87. doi: 10.1093/jnci/djs451. Epub 2012 Dec 12.

42.

18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.

Groheux D, Giacchetti S, Delord M, Hindié E, Vercellino L, Cuvier C, Toubert ME, Merlet P, Hennequin C, Espié M.

J Nucl Med. 2013 Jan;54(1):5-11. doi: 10.2967/jnumed.112.106864. Epub 2012 Dec 4.

43.

Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT.

Vercellino L, Groheux D, Thoury A, Delord M, Schlageter MH, Delpech Y, Barré E, Baruch-Hennequin V, Tylski P, Homyrda L, Walker F, Barranger E, Hindié E.

Clin Nucl Med. 2012 Nov;37(11):1065-8. doi: 10.1097/RLU.0b013e3182638e7e.

PMID:
22996235
44.

Additional diagnostic value of hybrid SPECT-CT systems imaging in patients with differentiated thyroid cancer.

Toubert ME, Vija L, Vercellino L, Banayan S, Faugeron I, Berenger N, Meas T, Marzola MC, Chondrogiannis S, Hindié E, Rubello D.

Am J Clin Oncol. 2014 Jun;37(3):305-13. doi: 10.1097/COC.0b013e3182568fdb. Review.

PMID:
22781388
45.

Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse.

Groheux D, Hindié E, Giacchetti S, Delord M, Hamy AS, de Roquancourt A, Vercellino L, Berenger N, Marty M, Espié M.

J Nucl Med. 2012 Feb;53(2):249-54. doi: 10.2967/jnumed.111.094045. Epub 2012 Jan 12.

46.

Lymphoscintigraphy can select breast cancer patients for internal mammary chain radiotherapy.

Hindié E, Groheux D, Hennequin C, Zanotti-Fregonara P, Vercellino L, Berenger N, Toubert ME, Maylin C, Vilcoq JR, Espié M.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1081-8. doi: 10.1016/j.ijrobp.2011.09.016. Epub 2011 Dec 13. Review.

PMID:
22172908
47.

The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.

Groheux D, Giacchetti S, Espié M, Vercellino L, Hamy AS, Delord M, Berenger N, Toubert ME, Misset JL, Hindié E.

J Nucl Med. 2011 Oct;52(10):1526-34. doi: 10.2967/jnumed.111.093864. Epub 2011 Aug 30.

48.

Lingual thyroid imaging with ¹²³I SPECT/CT.

Vercellino L, Alaoui NI, Faugeron I, Bérenger N, de Labriolle-Vaylet C, Hindié E, Toubert ME.

Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1173. doi: 10.1007/s00259-011-1747-7. Epub 2011 Mar 11. No abstract available.

PMID:
21394505
49.

Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.

Toubert ME, Vercellino L, Faugeron I, Lussato D, Hindie E, Bousquet G.

Thyroid. 2011 Apr;21(4):451-4. doi: 10.1089/thy.2010.0270. Epub 2011 Mar 8.

PMID:
21385075
50.

Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy-FDG-PET/CT.

Hindié E, Sarandi F, Banayan S, Groheux D, Rubello D, Vercellino L, Toubert ME, Moretti JL, Lebbé C.

PET Clin. 2011 Jan;6(1):9-25. doi: 10.1016/j.cpet.2011.01.001. Epub 2011 Feb 23.

PMID:
27156352

Supplemental Content

Loading ...
Support Center